EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout

Xinye Yang, Yong Li, Shengqiang Pan, Facheng Ma, Hong Chen, Jinhui Deng, Jie Yue, Qijie Gong, Mi Zheng, Ying Zeng, Jing Li, Yingjun Zhang und 2 weitere

Journal of Medicinal Chemistry · 22.08.2024 · 67 (16) · 14668-14691

DOI: 10.1021/acs.jmedchem.4c01480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 07.08.2024. Verfasst von Xinye Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: HEC Pharm Group, HEC Research and Development Center, Dongguan 523871, China. Hauptthemen laut MEDLINE: Xanthine Oxidase, Hyperuricemia, Gout, Organic Anion Transporters. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Province Funds for Distinguished Young Scientists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main uric acid-lowering agents in clinical use for hyperuricemia and gout are xanthine oxidase (XO) inhibitors or urate transporter 1 (URAT1) inhibitors. While these therapies can partially control the disease, they have various limitations. The development of XO/URAT1 dual inhibitors offers the potential to enhance therapeutic potency and reduce toxicity compared with single-target inhibitors. Through scaffold hopping from the XO inhibitor febuxostat (2) and the URAT1 inhibitor probenecid (3), followed by structure-activity relationship (SAR) studies, we identified compound 27 as a potent dual inhibitor of XO and URAT1. Compound 27 demonstrated significant dual inhibition in vitro (XO IC50 = 35 nM; URAT1 IC50 = 31 nM) and exhibited favorable pharmacology and pharmacokinetic (PK) profiles in multiple species including monkeys. Furthermore, toxicity studies in rats and monkeys revealed general safety profiles, supporting that compound 27 emerges as a promising novel drug candidate with potent XO/URAT1 dual inhibition for the treatment of gout.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Xanthine OxidaseHyperuricemiaGoutOrganic Anion TransportersOrganic Cation Transport ProteinsAnimalsStructure-Activity RelationshipHumansRatsAdministration, OralRats, Sprague-DawleyMaleMacaca fascicularisFebuxostatDrug DiscoveryEnzyme InhibitorsGout SuppressantsBiological AvailabilityProbenecid

Substanzen

Xanthine OxidaseOrganic Anion TransportersSLC22A12 protein, humanOrganic Cation Transport ProteinsFebuxostatEnzyme InhibitorsGout SuppressantsProbenecid

Autor:innen und Institutionen

  • HEC Pharm Group, HEC Research and Development Center, Dongguan 523871, China.
  • Laboratory of Drug Design and Discovery, Department of Chemistry, China Pharmaceutical University, Nanjing 211198, China.

ORCID-Profile: Xiaojin Zhang

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Province Funds for Distinguished Young Scientists

Zitieren

APA

Yang, X., Li, Y., Pan, S., Ma, F., Chen, H., Deng, J., Yue, J., Gong, Q., Zheng, M., Zeng, Y., Li, J., Zhang, Y., Wang, X., & Zhang, X. (2024). Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout. Journal of Medicinal Chemistry, 67(16), 14668-14691. https://doi.org/10.1021/acs.jmedchem.4c01480

Vancouver

Yang X, Li Y, Pan S, Ma F, Chen H, Deng J, et al. Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout. Journal of Medicinal Chemistry. 2024;67(16):14668-14691. doi:10.1021/acs.jmedchem.4c01480

BibTeX
@article{Yang2024,
  author = {Yang, Xinye and Li, Yong and Pan, Shengqiang and Ma, Facheng and Chen, Hong and Deng, Jinhui and Yue, Jie and Gong, Qijie and Zheng, Mi and Zeng, Ying and Li, Jing and Zhang, Yingjun and Wang, Xiaojun and Zhang, Xiaojin},
  title = {Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {16},
  pages = {14668--14691},
  doi = {10.1021/acs.jmedchem.4c01480}
}
Kostenlos starten →